Evidence map›Paper›PMID 41609816›Full record

ArticleEuropean biophysics journal : EBJ2026

Multiscale characterization of lipid bilayer disruption induced by Methyl-β-cyclodextrin (MβCD).

Wisnu Arfian Anditya Sudjarwo, Jose L Toca-Herrera

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wisnu Arfian Anditya SudjarwoDepartment of Natural Sciences and Sustainable Resources, BOKU University, Institute of Biophysics, Muthgasse 11/1/2, Vienna, 1190, Austria. wisnu.sudjarwo@boku.ac.at.ORCID http://orcid.org/0009-0004-1594-911X
Jose L Toca-HerreraDepartment of Natural Sciences and Sustainable Resources, BOKU University, Institute of Biophysics, Muthgasse 11/1/2, Vienna, 1190, Austria. jose.toca-herrera@boku.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the biophysical impacts of methyl-β-cyclodextrin (MβCD) on supported lipid bilayers composed of DPPC/POPE (1:1) and DPPC/POPE/Chol (1:1:2). Using Quartz Crystal Microbalance with Dissipation (QCM-D), Atomic Force Microscopy (AFM) imaging and force–distance (F–D) curve analysis, we monitored vesicle fusion, assessed bilayer symmetry, and evaluated mechanical stability before and after MβCD treatment. The DPPC/POPE bilayer initially showed a distinct “kink” in its F–D curve and a single breakthrough force, indicating a relatively asymmetric and heterogenous structure. Upon MβCD treatment, the bilayer exhibited symmetry, as evidenced by breakthrough force profiles. Similarly, the cholesterol-containing DPPC/POPE/Chol bilayers displayed two breakthrough points, signifying distinct lipid domains, higher rigidity, and heterogeneity. After one hour of MβCD treatment, these bilayers became more homogeneous and showed a single breakthrough peak—evidence of successful cholesterol or phospholipid extraction. Breakthrough force histograms reinforced these findings by revealing substantial shifts in force distributions. Complementary dynamic light scattering (DLS) and zeta potential measurements confirmed vesicle size and surface charge, while QCM detected notable mass loss in cholesterol-rich bilayers at elevated temperatures. Collectively, these findings underscore the role of cholesterol in bilayer architecture and validate MβCD as an effective modulator of bilayer composition and symmetry.

Indexed as

Atomic force microscopyCholesterol extractionLipid bilayerMethyl-β-cyclodextrinQuartz crystal microbalance with dissipation

Identifiers

PMID41609816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.